Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma (Q24602657)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

C P Reynolds

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Susan L. Cohn

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

12

Stephan A Grupp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

10

Katherine K Matthay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Andrew L Gilman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

M Fevzi Ozkaynak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Wendy B London

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Susan G Kreissman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Helen X Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Malcolm Smith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Barry Anderson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Judith G Villablanca

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Hiro Shimada

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Robert Seeger

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Allen Buxton

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Ralph A Reisfeld

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Steven D Gillies

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

John M Maris

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Paul M Sondel

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Children's Oncology Group

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1324-1334

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

14 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Adoptive cell therapy for the treatment of patients with metastatic melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

A mechanism for neutrophil-mediated lysis of human neuroblastoma cells

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086629

Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity

28 November 2018

1 reference

12 December 2020

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

12 December 2020

An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody

1 reference

12 December 2020

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

1 reference

12 December 2020

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord

1 reference

12 December 2020

In vivo binding and antitumor activity of Ch14.18

1 reference

12 December 2020

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

12 December 2020

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma

1 reference

12 December 2020

Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients

1 reference

12 December 2020

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA0911123

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20879881%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2 references